Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

T Cell differentiation Phosphoproteomic experiment

ABSTRACT: D10 T cells were treated with a variety of conditions to determine rapid changes in the phosphoproteome as cells begin differentiating

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): T Cell

SUBMITTER: Richard Cattley

LAB HEAD: William Hawse

PROVIDER: PXD025506 | Pride | 2021-11-02

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	A1.mgf	Mgf
	A1_Time0_1.raw	Raw
	A2.mgf	Mgf
	A2_Time0_2.raw	Raw
	A3.mgf	Mgf

Items per page:

1 - 5 of 84

Similar Datasets

Drug effects on Th17 differentiation

Project description:Determine the effect of apilimod and rapamycin on differentiating Th17 cells.

2024-12-16 | PXD046122 | Pride

Phosphoproteomic and transcriptomic profiling of ALK inhibition

Project description:Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals important conserved oncogenic pathways.

| PRJEB25635 | ENA

Effects of MINCH exposure on the phosphoproteome of differentiating human SGBS adipocytes

Project description:Here, we evaluated the molecular effects of MINCH exposure, as primary metabolite of the DEHP substitute DINCH, on the phosphoproteome profiles of differentiating SGBS adipocytes. This study includes data on rosiglitazone differentiated controls, 10 µM MINCH exposure, and exposure to the selective PPAR inhibitor GW9662, as well as combinations thereof.

2025-08-05 | PXD059416 | Pride

Phosphoproteomic response in nitrosamine-exposed mice

Project description:The aim of this study was to characterize ATM/ATR substrate motif specific phosphoproteome (phospho-SQ/TQ) in response to N-nitrosodimethylamine (NDMA) in mice. Motif specific phosphorylation were measured using quantitative LC-MS/MS based on TMT labeling.

2021-02-10 | PXD021142 | Pride

Network-based elucidation of colon cancer drug resistance by phosphoproteomic time-series analysis

Project description:Aberrant signaling pathway activity is a hallmark of tumorigenesis and progression, which has guided targeted inhibitor design for over 30 years. Yet, adaptive resistance mechanisms, induced by rapid, context-specific signaling network rewiring, continue to challenge therapeutic efficacy. By leveraging progress in proteomic technologies and network-based methodologies over the past decade we developed VESPA—an algorithm designed to elucidate mechanisms of cell response and adaptation to drug perturbations—and used it to analyze 7-point phosphoproteomic time series from colorectal cancer cells treated with clinically-relevant inhibitors and control media. Interrogation of tumor-specific enzyme/substrate interactions accurately inferred kinase and phosphatase activity, based on their inferred substrate phosphorylation state, effectively accounting for signal cross-talk and sparse phosphoproteome coverage. The analysis elucidated time-dependent signaling pathway response to each drug perturbation and, more importantly, cell adaptive response and rewiring that was experimentally confirmed by CRISPRko assays, suggesting broad applicability to cancer and other diseases.

2023-03-09 | GSE224396 | GEO

Phosphoproteomic analysis in Glioblastoma in response to AZD1775

Project description:The aim of this study was to characterize phosphoproteome in response to AZD1775 in patient derived xenografts (PDX) lines and clinical specimens in glioblastoma. Tyrosine and motif specific serine and threonine phosphorylation were measured using quantitative LC-MS/MS based on TMT labeling.

2022-10-13 | PXD018782 | Pride

Phosphoproteome dynamics during differentiation of SGBS adipocytes

Project description:Here, we identified temporal dynamics of the phosphoproteome during adipocyte differentiation in the human SGBS cells, applying untargeted proteomics in combination with enrichment strategies for phosphorylated peptides. Samples were taken at initiation of differentiation, at an intermediate and terminal time point.

2024-06-13 | PXD045770 | Pride

Phosphoproteomic analysis of UBQLN2 mutant cells

Project description:In the project “Phosphoproteomic analysis of UBQLN2 mutant cells” by Laura Strohm, Zehan Hu, Jörn Dengjel, and Christian Behrends eight sets of SILAC experiments were performed, two times four biological replicates, comparing proteome and phosphoproteome of control and UBQLN2 mutant, patient-derived lymphoblasts (LCLs).

2022-06-28 | PXD029730 | Pride

Phosphoproteome dynamics during differentiation of 3T3-L1 adipocytes

Project description:Here, we identified temporal dynamics of the phosphoproteome during adipocyte differentiation in the murine 3T3-L1 cells, applying untargeted proteomics in combination with enrichment strategies for phosphorylated peptides. Samples were taken at initiation of differentiation, at an intermediate and terminal time point.

2024-06-13 | PXD045778 | Pride

Temporal single-cell transcriptomic profiling of cardiac differentiation in human induced pluripotent stem cells with NOTCH1 mutations

Project description:Pathological variants in NOTCH1 have been implicated in multiple types of congenital heart defects including bicuspid aortic valve and hypoplastic left heart syndrome (HLHS). To probe how NOTCH1 deficiency affects cardiac development, we generated homozygous NOTCH1 knockout (N1KO) human induced pluripotent stem cells (iPSCs). We then ran single-cell RNA-seq to temporally profile transcriptomic changes during cardiac differentiation in wild type (WT) and N1KO iPSCs. We collected differentiating cells at multiple time points corresponding to different development stages, i.e., Day 0 (D0: pluripotent stem cell), D2 (mesoderm), D5 (cardiac mesoderm), D10 (cardiac progenitor), D14 (early cardiomyocyte), and D30 (fetal cardiomyocyte). Single-cell transcriptomics analysis reveals that NOTCH1 disruption impairs human ventricular cardiomyocyte differentiation and proliferation through balancing cell fate determination of cardiac mesoderm toward the first heart field, second heart field, and epicardial lineages.

2022-12-21 | GSE196632 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data